NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage
04 mars 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
27 févr. 2024 11h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Feb. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Appoints Timothy Henrichs as Chief Financial Officer
31 janv. 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that...
NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer
20 déc. 2023 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Reports Third Quarter 2023 Financial Results
20 nov. 2023 17h30 HE
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Announces CareFirst BCBS Policy Coverage
15 nov. 2023 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Secures $3 Million Financing
14 nov. 2023 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device
08 nov. 2023 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders
26 sept. 2023 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Reports Second Quarter 2023 Financial Results
21 sept. 2023 08h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that...